Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Incident CVD risk in prolactinoma elevated only in male patients

09 Nov 2017

Men with prolactinoma are at an increased risk of developing cardiovascular disease (CVD), whereas there is no evidence to suggest such an increase in female patients, according to a study.

Researchers drew data from The Health Improvement Network database, identifying 2,233 patients with prolactinoma and 10,355 controls matched according to sex, age, body mass index and smoking status.

The primary outcome was any incident CVD (myocardial infarction, angina pectoris, stroke, transient ischaemic attack or heart failure), the sex-specific adjusted incidence rate ratios (aIRRs) of which were calculated using Poisson regression. Sensitivity analyses were also performed.

The composite CVD outcome occurred in 54 prolactinoma patients and 180 controls during the 6-year observation period, resulting in an incidence rate of 1.8 and 14.8 per 1,000 person-years in females and males, respectively.

Estimated aIRRs for CVD were 0.99 (95 percent CI, 0.61 to 1.61; p=0.968) in female patients and 1.94 (1.29 to 2.91; p=0.001) in male patients. The gender-specific difference in the incidence of CVD was maintained through sensitivity analyses limited to patients with documented record of dopamine agonist treatment and those with newly diagnosed prolactinoma.

Researchers pointed out that the CVD risk in male patients remained elevated even in the presence of concurrent documented treatment with dopamine agonist. Potential mechanisms underlying the association between prolactinoma and CVD might include long-standing hyperprolactinaemia and its consequences, as well as hypopituitarism and its management.

The impact of the present gender-specific finding on the long-term mortality of prolactinoma patients has yet to be elucidated, researchers added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.